A groundbreaking medical study, the SuperSaturated Oxygen Comprehensive Observational REgistry (SSCORE), has commenced with enrolling its first patient. This prospective study aims to demonstrate further the effectiveness of SuperSaturated Oxygen (SSO2) Therapy in mitigating heart failure and mortality in patients experiencing left anterior descending ST-elevation myocardial infarction (LAD STEMI) heart attacks.

LAD STEMI heart attacks, often known as “widow makers,” pose a substantial risk to patients due to their high mortality rate. SSORE will additionally gather data to explore the potential cost savings for healthcare systems by preventing heart failure, which typically requires lifelong palliative treatments.

SSO2 Therapy has been demonstrated to significantly reduce damage to cardiac muscle in heart attack patients following angioplasty and stenting. The level of muscle damage is crucial in predicting future outcomes, including hospital readmission and heart failure development. The therapy delivers high dissolved oxygen levels directly to the affected heart muscle.

The Minneapolis Heart Institute, an early adopter of SSO2 Therapy, played a pivotal role in enrolling the first patient in the study. Dr. M. Nicolas Burke, Director of Cardiovascular Emergency Services, emphasized the importance of SSO2 in reducing infarct size and improving patient outcomes.

ZOLL TherOx General Manager Matt Rochner highlighted the potential of SSO2 Therapy to not only enhance patient outcomes but also reduce long-term healthcare costs associated with managing heart failure. The collaboration between ZOLL TherOx and the Minneapolis Heart Institute aims to gather further clinical and economic data to establish SSO2 Therapy as the standard of care for LAD STEMI patients.

Source link: http://www.businesswire.com/news/home/20240923128741/en/ZOLL-Enrolls-First-Patient-in-Groundbreaking-SSCORE-Commercial-Registry-at-Minneapolis-Heart-Institute-at-Abbott-Northwestern-Hospital-Minneapolis-MN

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.